IME ScreeningPort’s mission is to bridge the gap between basic academic research and the life sciences industry in the field of drug discovery and development. With state-of-the-art infrastructure at its location in Hamburg, established processes and innovative technologies, IME-SP positioned itself as a world-leading contract research organization for small-molecule screening, particularly for targets identified by academic partners.
The IME SP directs its efforts onto the development of biological assay systems, high-throughput drug discovery (i.e. high-throughput screening, high-content screening and virtual screening), and the identification of diagnostic biomarkers (including those used for companion diagnostics in preclinical/clinical studies and pharmacological bioinformatics).